A s the volume of safety information available to practitioners from a variety of sources steadily increases, an important question arises: With whom do you share or pass the information to when something is relevant to your practice?
The sources for safety information have increased tremendously. E-mail subscriptions and RSS feeds, blogs, Facebook, and other social media formats offer additional resources for safety details. Each source may hold something of relevance, and finding the time to follow each becomes a challenge.
As busy practitioners, most of us rely on information being pushed to us through e-mail subscriptions, rather than pulling information from a Web site without being prompted. We scan incoming e-mail messages and newsletters for key words or phrases, triggering a click to read more about the story, event, or announcement.
CLASSIFICATION OF SIGNIFICANT POSTMARKETING DRUG SAFETY ISSUES GUIDANCE DOCUMENT
The US Food and Drug Administration (FDA) offers a series of guidance documents that ''represent the Agency's current thinking on a particular subject.'' 1 Guidance documents are developed within the FDA and are made available for public comment prior to becoming finalized. In a draft guidance document posted in early March 2012, the FDA's Center for Drug Evaluation and Research (CDER) intends to classify significant postmarketing drug safety issues as priority, standard, or emergency and direct resources toward safety issues posing the greatest risk to patients. 2 This guidance document is one of the initiatives CDER has taken to strengthen the management of postmarketing evaluations and to bring accountability to the postmarketing safety review as currently established for premarket review of drugs through the Prescription Drug User Fee Act of 1992 (PDUFA).
Safety issues identified as significant for tracking purposes are those that have the potential to lead to any of the following: withdrawal of an approved drug or withdrawal of an approved indication, limitations on the use of a drug, certain labeling changes, establishment or modification of a risk evaluation and mitigation strategy (REMS), and requirements for specific sponsorsupported trials or studies, among others. The proposed guidance establishes a framework for prioritizing identified significant safety issues as priority, standard, or emergency, allowing CDER staff to manage announcements and communication to health care professionals and patients in a timely manner regarding safety risks with the greatest public health significance.
After the prioritization of the issue, hazard assessment criteria will be applied followed by evaluation of modulating factors to classify the safety issue, resulting in a ranking of priority or standard. Priority safety issues may be elevated to emergency status if they have involved fatalities, if they have the potential to affect a large number of patients, and if lives can be saved or serious harm prevented by prompt action. This is a positive step for CDER in the ongoing effort to become more transparent and provide safety information to health care providers and the public in a timely manner when solid information is available. It is unclear whether this will highlight or change the visual cues in communication from the FDA to practitioners to help with routing or sharing of important safety information.
EXAMPLE SAFETY ANNOUNCEMENTS
The FDA recently issued a statement regarding the increased risk of cardiovascular death following azithromycin therapy due to an increase in the QTc interval, based on a study published in a prominent medical journal. 3 With the potential to impact large numbers of patients and a possibly fatal outcome, this type of announcement warrants the use of an *Clinical Pharmacy Specialist, Legacy Health System, Portland, Oregon Hospital Pharmacy emergency level communication method as the FDA completes their review of the information. Promoting the study and identified potential risk through an FDA statement is helpful to practitioners by highlighting the new information and initiating conversations within the organization to assess the relevance of the study to patient populations.
Another example of a significant labeling change posted in November 2010 involved trastuzumab (Herceptin; approved for treatment of HER2overexpressing cancers) and new information on fatal fetal pulmonary hypoplasia. 4 Once a labeling change is identified, it may be appropriate to pass the information along to the appropriate practitioner groups (oncology providers) and the information technology (IT) team. This is an example of a safety notification that could develop into an alert for ordering providers, with notification of a patient's pregnancy status or potential when ordering trastuzumab. It is also important to understand when the IT interactions or alert database is updated. Does the monthly or quarterly update contain clinically significant safety information? How are the alerts identified and updated for inclusion? An ongoing challenge for IT systems is maintenance of information not routinely provided by vendors, and this should be considered in the decision to add additional alerts.
Managing incoming and updated safety information remains a daunting task. The efforts of the FDA to improve communication strategies are welcome, as practitioners incorporate new information into current care of patients.
